A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

(2014) Yun Shi et al.   BREAST CANCER RESEARCH

Humoral response to a viral glycan correlates with survival on PROSTVAC-VF

(2014) C. T. Campbell et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pertuzumab Protects the Achilles' Heel of Trastuzumab--Emtansine

(2013) W. R. Gwin et al.   CLINICAL CANCER RESEARCH

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients

(2013) Tao Qin et al.   OncoTargets and Therapy

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

(2012) Erika Hamilton et al.   Journal of Translational Medicine

MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients

(2011) Richard Harrop et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients

(2010) Richard Harrop et al.   JOURNAL OF IMMUNOTHERAPY

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

(2009) Mary L. Disis et al.   JOURNAL OF CLINICAL ONCOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non-Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine

(2008) B. Garcia et al.   CLINICAL CANCER RESEARCH

Cancer vaccines: on the threshold of success

(2008) Leisha A Emens   EXPERT OPINION ON EMERGING DRUGS